Why the study?
Is serum myosin light chain 3 (MLC-3) a useful marker for muscle breakdown in patients with neuromuscular diseases?
Is serum myosin light chain 3 (MLC-3) a useful marker for muscle breakdown in patients with neuromuscular diseases?
Answers are grounded in this paper and cite their sources.
Circulating MLC-3 may serve as a useful biomarker for muscle breakdown in both myopathies and neurogenic disorders.
A radioimmunoassay for human skeletal muscle myosin light chain 3 (MLC-3) was developed. The serum level of MLC-3 was evaluated in 143 patients suffering from neuromuscular diseases. Increased MLC-3 level was observed in muscular dystrophies. There were significant positive correlations between serum levels of MLC-3 and creatine kinase (CK) in Duchenne and limb-girdle type muscular dystrophy, but the regression lines were different. Patients with neurogenic amyotrophy, especially amyotrophic lateral sclerosis, also showed elevated MLC-3 levels with or without high CK, and the frequency of increase in MLC-3 was greater than that of CK. The results of the present study suggest that circulating MLC might be a useful marker for muscle breakdown not merely in myopathies but in neurogenic disorders.
No takes yet. Share an insight, caveat, or question.
Konagaya et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: